Catalyst
Slingshot members are tracking this event:
Amgen's (AMGN) BLINCYTO earns FDA approval for relasped or refractory B-cell acute lymphoblastic leukemia
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 13, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Blincyto, Fda Approval, Relapsed/refractory Acute Lymphoblastic Leuke
